LGM
BBNX

Lykos Global Management’s Beta Bionics BBNX Stock Holding History

Lykos Global Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$305K – 6
2025
Q4 		$305K Buy
+10,000
New +$267K 0.22% 33

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lykos Global Management's BBNX Position: Q1 2026 in Review

Lykos Global Management sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 10,000 shares — an estimated $305K sold.

Lykos Global Management first reported a position in BBNX in Q4 2025 and held it in 1 quarter. The position peaked at $305K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Lykos Global Management reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • Lykos Global Management sold 10,000 Beta Bionics shares in Q1 2026, an estimated $305K.
  • Lykos Global Management first reported a position in Beta Bionics in Q4 2025 and held it in 1 quarter.
  • Lykos Global Management's Beta Bionics position peaked at $305K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Lykos Global Management's 13F filing for Q1 2026, filed 15 May 2026.